It is well established that DNA and proteins undergo dynamic chemical modifications that influence their function. For instance, methylation of cytosine residues in DNA to form 5-methylcytosine (5mC) can have widespread effects on gene expression by recruiting specific DNA-binding proteins 1 . Similarly, phosphorylation of proteins -a reversible chemical event that was initially thought to be restricted to just a few targets -is involved in nearly every aspect of cellular physiology 2 . However, until recently, mRNA had not been shown to be extensively subjected to such chemical modifications that might alter its function.
It is well established that DNA and proteins undergo dynamic chemical modifications that influence their function. For instance, methylation of cytosine residues in DNA to form 5-methylcytosine (5mC) can have widespread effects on gene expression by recruiting specific DNA-binding proteins 1 . Similarly, phosphorylation of proteins -a reversible chemical event that was initially thought to be restricted to just a few targets -is involved in nearly every aspect of cellular physiology 2 . However, until recently, mRNA had not been shown to be extensively subjected to such chemical modifications that might alter its function.
Two groups showed in 2012 that a large fraction of cellular mRNA contains adenosine residues that are methylated to form N 6 -methyladenosine (m 6 A) 3,4 . In addition, the characterization of adenosine methyltransferases and m 6 A demethylating enzymes has provided insights into the pathways that dynamically regulate adenosine methylation in mRNA and how this process contributes to human disease 3, 5, 6 . Collectively, these studies demonstrate for the first time that mRNA is susceptible to dynamic, reversible chemical modification. Thus, analogous to methylation of DNA and phosphorylation of proteins, adenosine methylation in mRNA represents an additional layer of regulation that can potentially alter mRNA function and influence the way that genes are expressed.
A flurry of recent discoveries has also pointed to important roles for m 6 A in regulating crucial cellular pathways and processes, which highlights the potentially broad role for m 6 A in regulating mRNA fate
. In this Review, we discuss the discovery of the m 6 A modification, including early studies that first revealed the existence of m 6 A and more recent studies that have profiled the features of m 6 A on a global scale. We also analyse the strengths and limitations of current methods used to study m 6 A and highlight improvements that are needed to move the field forwards. Furthermore, we emphasize our current knowledge of adenosine methylation and demethyl ation pathways in mammalian systems and the insights that studies of these pathways have provided for the role of m 6 A in human disease. Last, we discuss the questions that are driving m 6 A research and the implications that their answers might have on our understanding of RNA biology.
Serendipitous discovery of m 6
A The finding that polyadenylated RNA contains m 6 A was a serendipitous discovery made by several groups that were characterizing the mRNA 5ʹ structure in mammalian cells in 1974 (REFS 7, 8) , which was validated by others the following year [9] [10] [11] [12] . The original goal of these studies was to characterize the methylation of the recently described 5ʹ-cap of mRNAs. These studies were made possible because radioactive [ 3 H]-methionine, the methyl source in most biochemical reactions, had become commercially available with high specific activity. [ 3 H]-methionine can be applied to cells and is then metabolically incorporated into S-adenosylmethionine (SAM), the enzymatic co factor that participates in many methylation reactions in the cell.
After digestion of the poly(A) RNA, it was clear that the radioactivity was not confined to the 5ʹ-caps. Radioactivity was also detected in the mononucleotides, with most found in a modified nucleotide, m 6 A 7, 8 . In most studies, m 6 A was the only modified base that was detected, although one study also reported the presence of 5-methyl-cytosine but only at one-quarter of the abundance of m 6 A 12, 13 . Radioactive methyl groups were also found within what seemed to constitute an extended cap structure 14 
. The finding of m 6 A in RNAs was not unprecedented, as m 6 A was known to be in bacterial tRNA and other non-coding RNAs (ncRNAs) [15] [16] [17] [18] [19] . However, these initial studies provided the first evidence that m 6 A is present in mammalian poly(A) RNA and in mRNA that is encoded by diverse viruses [20] [21] [22] [23] [24] . Subsequent studies showed that m 6 A is a prevalent nucleotide in poly(A) mRNA from nearly all higher eukaryotes and plants 7, 8 . The early studies examined poly(A) RNA, rather than mRNA. However, as mRNA is highly enriched in poly(A) RNA preparations, it was tempting to speculate that the m A residues per mRNA [7] [8] [9] [10] [11] [12] . This measurement relied on the assumption, which is now known to be incorrect, that m 6 A is evenly distributed in all cellular transcripts. Nevertheless, these early investigators made the seminal proposal that post-transcriptional methylation of adenosine residues in mRNA might influence the fate of mRNA in cells, which is potentially analogous to the functional consequences of protein modifications.
Reluctance to accept m 6 A Despite the interesting possibility that mRNA is regulated by adenosine methylation, there were very few studies that further investigated the original findings from m 6 A. The initial interest in m 6 A was mostly abandoned owing to considerable reluctance to accept the idea that this modification is biologically relevant. One concern was that m 6 A could have arisen from contamination from small amounts of known m 6 A sources 25 , such as ribosoma l RNA (rRNA) 26 and small nucleolar RNAs (s noRNAs) 27, 28 . Another factor was that these early studies used poly(A) RNA, which is often contaminated with mitochondrial RNA, tRNA and certain rRNAs owing to their poly(A) tracts [29] [30] [31] . Indeed, most preparations of poly(A) RNA invariably contain rRNA bands. In some studies, rigorous gradient purification methods were used to remove this persistent contaminant 32 , which supported the idea that m 6 A is a constituent of mRNA. However, most studies did not use these approaches, questioning the relevance of studies using poly(A) RNA. Indeed, it is now known that up to 50% of the RNA pool in poly(A) RNA fractions constitutes diverse ncRNA species [33] [34] [35] [36] . Box 1 | Physiological processes linked to N 6 -methyladenosine Obesity Diverse mutations within intron 1 of human fat mass and obesity-associated protein (FTO) have been found and are associated with increased body weight 105 . Carriers of one or two copies of the mutant allele are on average 1.7 kg or 3.5 kg, respectively, heavier than individuals with normal alleles 105 .
Fto
-/-mice have lower body mass 106 , whereas FTO overexpression leads to increased food intake and obesity 107 . The intronic mutations in humans probably influence FTO gene expression, although a direct mechanistic connection between FTO and body mass has not been established.
Synaptic signalling
Fto-knockout mice have impaired dopamine release, reduced dopaminergic receptor responses and an altered locomotor response to cocaine 42 . Select mRNAs that are involved in dopaminergic signalling pathways are hypermethylated in these mice, which may underlie their neurobiological and behavioural phenotypes. However, the consequences of mRNA hypermethylation on transcript stability and protein production are complex, and further studies are needed to determine the effects of FTO-induced demethylation in specific neuronal subtypes and signalling pathways.
Cancer
Recent genome-wide association studies have demonstrated that intron 1 FTO mutations are also risk factors for oestrogen receptor-negative breast cancer 102 . Additional studies have identified mutations within intron 8 of FTO, which lead to increased melanoma risk that is independent of any effects on body mass index 108 . These studies identify for the first time FTO single nucleotide polymorphisms, which are not associated with the body mass index but which predispose to cancer. Although it remains to be determined how these intron 8 mutations affect the demethylase activity of FTO, they are postulated to influence FTO mRNA expression levels.
Sperm development
Consistent with the high expression level of ALKBH5 (α-ketoglutarate-dependent dioxygenase alkB homologue 5) in testes, Alkbh5-knockout mice exhibit reduced testicular size and abnormal morphology 6 . They also have impaired spermatogenesis and increased apoptosis, which probably contributes to the reduced fertility that has been observed in these mice. This phenotype may be explained in part by the altered expression levels of genes in the spermatogenesis and p53 apoptotic pathways observed in Alkbh5  -/-mice   6 ; however, whether hypermethylation of these mRNAs underlies their alternative expression pattern remains to be determined.
Stem cell differentiation N

6
-methyladenosine (m 6 A) is required for the self-renewal capacity of human embryonic stem cells and is found in crucial pluripotency regulators 63 ; dynamic changes in m 6 A levels are seen during stem cell differentiation 63 .
Circadian periods
The global methylation inhibitor 3-deazaadenosine (3-DZA) causes an extension of the normal circadian period both in cultured cells and in mice. Moreover, methylated RNA immunoprecipitation followed by sequencing (MeRIP-Seq) analysis shows that m 6 A decreases in several clock genes following 3-DZA treatment in cells. This correlates with prolonged nuclear retention in clock transcripts Per2 (period circadian clock 2) and Arntl in cell lines 109 . Similar results were also observed after methyltransferase-like 3 (Mettl3) knockdown. Thus, adenosine methylation may influence the cyclic expression of mRNAs that encode clock genes.
Yeast meiosis mRNA methylation in Saccharomyces cerevisiae selectively occurs during meiosis 64 and is mediated by a core RNA methyltransferase complex. This complex, termed MIS, comprises inducer of meiosis 4 (Ime4; an orthologue of mammalian METTL3), muddled meiosis 2 (Mum2; an orthologue of the mammalian Wilms tumour 1-associated protein (WTAP)) and sporulation-specific with a Leu zipper motif protein 1 (Slz1) 64 . The MIS complex localizes to nucleoli during meiosis and is required for the proper time course of meiosis 75 .
Plant development m 6
A contributes to plant embryonic development and is required for normal growth patterns, apical dominance and plant development 57, 110 .
Drosophila melanogaster oogenesis m 6
A is required for Notch signalling during oogenesis on the basis of phenotypes seen in D. melanogaster cells that are deficient in the adenosine methyltransferase Ime4 In addition to the concern about a contamination artefact, another concern was that mutation of specific m 6 A sites did not result in a change in RNA fate in cells. For example, point mutations that depleted m 6 A within the src transcript of Rous sarcoma virus did not affect the nuclear location of the src transcript, RNA expression levels, splicing, translation, packaging of the RNA into virions or infectivity of the mutant virus 37, 38 . These studie s raised the possibility that m 6 A has a minimal impact on mRNAs. Another problem was that few endogenous mRNAs were shown to contain m 6 A. If m 6 A was indeed highly prevalent, it should have been seen in numerous cellular mRNAs. Although m 6 A was frequently detected in viral mRNAs 39 , the only endogenous mammalian mRNA that had been shown to contain m 6 A was pro lactin mRNA 40, 41 . Therefore, it was plausible that m 6 A was preferentially introduced into foreign mRNAs. The prevalence of m 6 A in poly(A) mRNA might reflect the incorporation of m 6 A into a small number of hypermethylate d cellular mRNAs.
Addressing these issues was a formidable challenge, as no methods existed that could globally detect m A-containin g poly(A) RNAs span a broad range of sizes, which range from fewer than 500 bases to over 7 kb 3 . This resembles the distribution expected for mRNAs, which suggests that mRNAs are the m 6 A-containing species in these blots. m 6 A immunoblots also enable changes in m 6 A levels to be measured. For example, the intensity of the m 6 A smear in the immunoblot differs markedly when comparing RNA derived from different tissues and cancer cell lines -the highest m 6 A levels are detected in the brain, heart and kidney 3 . m 6 A-containing mRNAs are low in the fetal brain but increase during development to a maximal level in the adult brain 3 . These data argued against initial theories suggesting that m 6 A might be a fixed feature of mRNA, like the 5ʹ-cap modification, and indicated that it functions as a tissue-specific regulato r of mRNA fate.
Finally, pulldown of the low-density lipoprotein receptor (Ldlr), metabotropic glutamate receptor 1 (Grm1) and D(1A) dopamine receptor (Drd1; also known as Drd1a) transcripts followed by m 6 A immunoblotting analysis revealed that each of these mRNAs is endogenously methylated in cells 3 .
Box 2 | Methyl code of the 5ʹ-cap mRNA
The mRNA cap is introduced in the nucleus by the attachment of a GTP to the first encoded nucleotide (N 1 ) at the 5ʹ end of a transcript. The GTP is attached by an unusual linkage, in which the 5ʹ hydroxyl group of the GTP is connected by three phosphates to the 5ʹ hydroxyl group of N 1 (REFS12,111) (see the figure) . The most well-characterized methyl group is found on the N 7 position of the essential guanosine (purple). N 7 methylation is required for mRNA export and subsequent recognition of the cap by the eukaryotic translation initiation factor 4E (eIF4E) 111 . Lack of this methyl group markedly reduces translational efficiency in standard in vitro translation reactions 112 . The first two nucleotides (N 1 and N 2 ) of the mRNA can also be methylated on the N 1 2ʹ hydroxyl (blue) to form 'cap-1' or on the 2ʹ hydroxyl of both the N 1 and N 2 (green) to form 'cap-2'. 5ʹ-caps that lack methyl groups on either N 1 or N 2 2ʹ hydroxyls are referred to as 'cap-0' (REF. 113 ). The first nucleotide in an mRNA is frequently an adenosine, which can be additionally methylated at the N 6 position (yellow) 14, 113 . The N 6 methylation seems to follow the 2ʹ-O-methylation and is probably mediated by a methyltransferase other than methyltransferase-like 3 (METTL3) or METTL14 (REF. 114 ). Thus, when considering the cap as an extended structure that comprises the 7-methylguanosine (m 
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The methylated transcriptome
The methylated transcriptome was first defined using methylated RNA immunoprecipitation followed by sequencing (MeRIP-Seq) and an essentially equivalent approach known as m A is a widespread mRNA modification and thus laid to rest many of the previous doubts regardin g whether m 6 A was indeed a prevalent modification in mRNA.
However, m 6 A was not found in all mRNAs or in only a few highly methylated mRNAs, but in ~25% of all transcripts. Hence, these studies ruled out earlier ideas that m 6 A might be an obligate feature of all mRNAs as a result of biogenesis or processing. Importantly, the distribution of m 6 A along the length of transcripts was nonrandom, which suggests that m 6 A has functional roles in mRNA 3, 4 . Moreover, mRNA methylation sites were typically found in portions that showed higher evolutionary conservation than other regions 3 , which further suggests that m 6 A has conserved regulatory roles. Importantly, although many transcripts were methylated in both brain and HEK293 cells, others were m ethylated in only one tissue 3 . This indicates that methylation is not exclusively regulated by cis-acting sequences in the mRNA and that trans-acting tissue-specific factors probably contribute to the specificity of methylation in different cell types. However, when a transcript was methyl ated in both tissues, the m 6 A peaks were typically localized to the same region of the transcript.
Interestingly, not all the m 6 A peaks detected by MeRIP-Seq were found in mRNAs. In the brain, for example, although 94.5% of m 6 A peaks were found within mRNAs, the rest mapped to several classes of (long) ncRNAs , including the well-known long ncRNAs X inactive specific transcript (XIST) and HOX transcript antisense RNA (HOTAIR) 3 . These data indicate that ncRNAs are also important targets of m A residues in their 5ʹ untranslated regions (UTRs) 3, 4 . Typically, the 5ʹ UTR of a transcript is relatively short; thus, the number of m 6 A residues per unit length within the 5ʹ UTR is strikingly high compared with other regions of the transcript 4 . Interestingly, the proportion of cellular mRNAs that have m 6 A in the 5ʹ UTR seems to exhibit tissuespecific differences 4, 43 , which indicates that regulation A-specific antibody was described in 1988 (REF. 27 ). It was initially used in studies to immunoprecipitate small nucleolar RNAs (snoRNAs) 27 and was commercialized by Synaptic Systems (Göttingen, Germany). A second antibody was used to study m A is present in a specific transcript. For example, biotinylated oligonucleotides have been used to pull down mRNAs that hybridize to specific target mRNAs followed by anti-m A is markedly impaired when using Thermus thermophilus (Tth) DNA polymerase, which can function as a reverse transcriptase 119 . The slowed reverse transcription can be detected by the reduced level of incorporated T in a DNA primer 119 . SCARLET SCARLET (site-specific cleavage and radioactive-labelling followed by ligation-assisted extraction and thin-layer chromatography) uses targeted nuclease digestion and radiolabelling steps combined with the well-known altered migration of m A stoichiometry and can potentially be used to recover any base in the transcriptome to determine whether it contains a modification. However, as detection of the m 6 A requires TLC, it cannot be adapted to a transcriptome-wide approach.
PacBio sequencing
The PacBio instrument uses a novel fluorescence detection technology, which relies on zero-mode waveguides 121 to detect the altered kinetics of base incorporation that is opposite to an m 6 A relative to an A during reverse transcription. This approach detects differences in the rate of T incorporation that is opposite an m 6 A versus an A when generating cDNA from an RNA template 43, 122 . However, this method requires complex instrumentation as well as purification of the specific target mRNA, and will therefore benefit from methodological simplification. by 5ʹ UTR m 6 A residues may be more frequently used in certain tissues than in others. Indeed, liver cells and liver-derived cells (HepG2) seem to have a higher proportion of 5ʹ UTR m 6 A than other tissues. However, thus far, no tissues have been identified that completely lack m 6 A 3 . m 6 A residues are also found in the 3ʹ UTR outside of the region adjacent to the stop codon 3 . However, these m 6 A residues were less abundant than the m 6 A residues near the stop codon. Furthermore, m 6 A residues were found within the coding sequence, but again, the relative abundance per unit length of the sequence was proportionately smaller than in other regions of the transcript. Finally, m 6 A was not found in poly(A) tails 3 , which is consistent with early metabolic labelling studies 25 . The enrichment of m 6 A residues near the stop codon and the 5ʹ UTR is markedly distinct from the binding properties of other known mRNA regulatory elements. For example, microRNA (miRNA)-binding sites are enriched at the 5ʹ and 3ʹ ends of the 3ʹ UTR 44 . Many other mRNA-binding proteins bind to the 3ʹ UTR of mRNAs 45 , which is also the most structured portion of the molecule 46 . Moreover, few mRNA-binding proteins show preferential binding to the 5ʹ UTR 45 . Hence, the enrichment of m 6 A residues in the 5ʹ UTR and around the stop codon is unusual compared with other mRNA regulatory elements and suggests unique regulator y functions for this modification.
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How is methylation targeted?
The asymmetric distribution of m 6 A residues in mRNA immediately raises the question of how this specificity is achieved. Analysis of the MeRIP-Seq-generated peaks using the motifdiscover y algorithm finding informative regulatory elements (FIRE) 47 identified the enrichment of GAC and AAC consensus motifs within these peaks -GAC being the most prominent. Variants of this motif with preferences for residues that are located 5ʹ and 3ʹ to the core motif were also found, including G[G/A]A*CU (the asterisk indicates a putative m 6 A) 3 . These motifs were found in nearly 90% of all m 6 A peaks 3 and, importantly, other motifs may exist for a smaller subset of m 6 A residues 3, 4 . It is noteworthy that the motifs that were identified by bioinformatic analysis of MeRIP-Seq data were remarkably similar to the motifs predicted using biochemical approaches in the 1970s 20, 24, [48] [49] [50] . These experiments relied on the digestion of mRNAs using ribonucleases that selectively cleave RNA after specific nucleotides and showed that the central adenosines in the GAC and in the less common AAC motifs are the methylation sites. Follow-up studies using in vitro methylation assays with purified nuclear extracts and synthetic RNAs showed that methylation only occurred on RNAs that contain a GAC sequence and not on variants, such as GAU or UAC, or GACG 51 . Furthermore, mutation of GAC sequences to GAU was sufficient to block adenosine methylation 38 . The sequences that were discovered by FIRE analysis of the MeRIP-Seq data set show that these m 6 A motifs apply to most cellular m 6 A-containing mRNAs. A-containing RNA to next-generation sequencing. In MeRIP-Seq, RNA is fragmented into ~100 nucleotide (nt)-long fragments. Smaller fragments can also be generated to obtain higher resolution 75 One of the immediate implications of finding very few methylation site motifs is that there are possibly only a few pathways that control and recognize methylation. A diversity of motifs would have suggested that there might be various methylating enzymes and m 6 Abindin g proteins, each linked to a specific motif consensus site. This would be analogous to the known diversity of kinases, which are generally linked to specific phosphoryl ation consensus sites in the proteome. Therefore, the relative consistency of m 6 A sites throughout the transcriptome suggests that there is a limited repertoire of 'readers' (m 6 A-binding proteins), 'writer s' (adenosine methyltransferases) and 'erasers' (m 6 A demethylating enzymes) for this modification.
The presence of such a short methylation motif raises the question: why are so few methylated in mRNAs? The most prominent m 6 A consensus motif, GAC, is found approximately every 64 nucleotides in RNA, which suggests that an average 2,000 nucleotide-long mRNA would have ~30 m 6 As distributed evenly along the length of the transcript. However, most transcripts lack m 6 A altogether 3 , and in m 6 A-modified transcripts m 6 A is usually found near the stop codon. Thus, the enrichment of m 6 A at specific GAC residues, especially residues near stop codons, suggests that additional factors determine whether a GAC is targeted for methylation. Structural features that are adjacent to the GAC sequence could be a possible determining factor. Nonetheless, m 6 A peaks are typically found within unstructured regions of RNA 4 rather than in loops or bulges of stem-loops. Hence, although the structure may contribute in some instances to specific methylation events, it does not seem to account for the overall distribution of m 6 A seen in the metagene analysis.
One mechanism that might enable region-specific methylation within mRNAs could be methyltransferase tethering. For example, tethering of a methyltransferase to 5ʹ UTR elements or near the stop codon could account for the distribution of methylated GAC motifs in these regions. This model is not fully consistent with our understanding of the subcellular localization of the adeno sine methyltransferase enzymes (see below) and does not explain m 6 As within the open reading frame, but it could account for some of the defining features of m A residues were clustered in the Rous sarcoma virus transcript 39 . These data are consistent with the idea that 'hot spots' of methylation occur in certain regions of mRNA, possibly as a result of a tethered methyltransferase. A global method for profiling m 6 A at single-nucleotide resolution will be important to determine whether the distribution of m 6 A in mammalia n mRNAs is compatible with a clustering model.
Enzymes that mediate m 6
A methylation Identifying the enzymes that catalyse adenosine methylation will be an important advance for delineating the regulation of mRNA methylation in cells. Several enzymes have been identified that seem to mediate physiological adenosine methylation in mRNA.
The METTL3-METTL14 complex. Early studies identified a large (>1 MDa) multiprotein complex that mediates adenosine methylation 52 . Nuclear preparations were capable of methylating RNA in a SAM-dependent manne r in vitro, and the substrate specificity matched the m 6 A consensus motif that had been established by biochemical methods 51 . Thus, mRNAs containing GAC were more efficiently methylated than mRNAs containing AAC, whereas other sequences, such as GAU, were typically unmethylated (FIG. 2a) . Importantly, this complex did not induce the formation of N,N-dimethyladenosine 51 , unlike various Lys methyltransferases, which can produce 'higher order' methylated forms of Lys, such as dimethylate d and trimethylated Lys 53 . Subsequent efforts focused on purifying the catalytic subunit of the methyltransferase complex 54 . The catalytic component was detected by its ability to crosslink to [ 3 H]-SAM, and was designated methyltransferase-like 3 (METTL3; also known as MTA70). Purification of the enzyme showed that it exhibited the predicted specificity towards GAC and AAC sequences in single-stranded RNA 55, 56 . Cloning of METTL3 revealed that it has a classic SAM-binding methyltransferase domain, which is consistent with its function 54 . Homologues in plants (MTA) 57 , Saccharomyces cerevisiae (inducer of meiosis 4 (Ime4)) 58 and Drosophila melanogaster (Ime4) 59 have also been identified.
Recent studies have begun to clarify other components of the METTL3 multiprotein complex. A proteomewide analysis of protein complexes identified a single interactor of METTL3, METTL14 (REF. 60 ). METTL14 is highly similar to METTL3 and is a predicted methyltransferase [61] [62] [63] . Subsequent studies confirmed that both METTL3 and METTL14 form complexes in cells and that purified METTL14 also selectively methylates 
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Small nuclear RNAs
(snRNAs). RNAs that associate with specific proteins and that are frequently involved in pre-mRNA processing events such as splicing. [61] [62] [63] . Furthermore, the methyltransferase activities of both METTL3 and METTL14 are synergistically increased when they are mixed 62, 63 . It is not clear why two methyl transferases are present in the methyl transferase complex, but it is possible that these highly similar enzymes can either function independentl y or that each has unique forms of regulation.
GAC sequences in vitro
Importantly, knockdown of either Mettl3 or Mettl14 results in reduced m 6 A peaks in most, but not all, m 6 A-containing mRNAs in mouse embryonic stem cells 63 , which confirms that METTL3 and METTL14 physiologicall y target mRNAs for methylation.
In addition to METTL14, Wilms tumour 1-associated protein (WTAP) was found to associate with METTL3-METTL14. The importance of this inter action was first established in yeast and Arabidopsis thaliana, in which the WTAP homologues Mum2 (muddled meiosis 2) and FIP37 (FKBP12-INTERACTING PROTEIN OF 37 kDa), respectively, were shown to associate with METTL3 and were required for efficient methylation of mRNA 57, 64 . Analysis of mammalian WTAP showed that it too is required in mammalian cells for cellular mRNA methylation 61, 62 . Although WTAP binds to Wilms tumour protein (WT1), this tumour suppressor oncogene is not involved in mRNA methylation, as knockdown of WT1 does not affect cellular m 6 A levels in mRNA 61 . WTAP seems to interact with numerous cellular proteins, thus, despite its name, many of its functions are unrelated to WT1 (REF. 65 ). WTAP, which lacks methyltransferase domains or activity, was shown to bind to the METTL3-METTL14 complex 61, 62 and to induce its localization to nuclear speckles
61
. Therefore, WTAP may facilitate mRNA methylation by translocating METTL3-METTL14 to nuclear speckles.
Where in the cell does methylation occur? Owing to the readily detectable levels of METTL3, METTL14 and WTAP in nuclear speckles 54, 61 , this is likely to be an important site for methylation. A nuclear site for methylation is also supported by early studies that showed that nuclear extracts contain methyltransferase activity 51, 66 . Additionally, WTAP knockdown prevents METTL3 localization to nuclear speckles and reduces cellular m 6 A levels 61 . The localization of METTL3 to nuclear speckle s suggests that this protein may methylate speckleassociate d RNAs, such as small nuclear RNAs (snRNAs) and pre-mRNA, and functions during splicing reactions (see below). Additional support for nuclear mRNA methylation comes from PAR-CLIP (photoactivatableribonucleoside-enhanced crosslinking and IP) analysis of METTL3-binding sites in the transcriptome, which revealed an exceptionally high number of binding sites in intronic mRNA sequences 61 . However, early studies also detected methyltransferase activity in cytosolic extracts, which supports the idea that at least some methylation could occur in the cytoplasm 51 . Cytoplasmic methylation would imply a role for m 6 A in the control of mRNA fates that do not affect splicing or nuclear export. Furthermore, the localization of METTL3 that was observed using different antibodies showed a granular cytoplasmic or perinuclear labelling 67 , and immunolabelling for the D. melanogaster homologue, Ime4, indicated some immunoreactivity in the cytoplasm 59 . Notably, METTL3 is expressed as both long and short alternatively spliced isoforms, which remain to be characterized 68, 69 . Conceivably, some of the variability in the immunolabelling and localization may reflect these isoforms.
The distribution of m 6 A within transcripts also supports the idea that mRNA methylation might occur in the cytosol. MeRIP-Seq analysis of m 6 A localization in the transcriptome shows that m 6 A residues are highly enriched around stop codons. Cellular recognition of stop codons is mediated solely by ribosomes that are bound to release factors 70 . Hence, stop codon-bound ribosomes could in principle tether a methyltransferase, which would result in stop codon-adjacent adenosine methylation. Importantly, ribosomes bound to stop codons have key regulatory roles in controlling nonsense-mediated decay and potentially other processes 71 . As ribosome function is predominantly cytosolic 72 , a ribosome-mediated methylation pathway would indicate a cytosolic location for methylation, at least for m 6 A residues that are proximal to stop codons.
Could other methyltransferases drive m
6 A formatio n? The possibility that additional methyltransferases have a role in adenosine methylation is supported by the fact that a small number of m6A peaks do not seem to contain the GAC or AAC consensus sites 3,4 . Furthermore, m 6 A can be found at the first position in many mRNAs after the 7-methylguanosine (m 7 G)-cap, which results in an m 7 Gpppm 6 Am (m 6 Am indicates N 6 ,2ʹ-Odimethyladenosine and p indicates a phosphate group) structure (see BOX 2 for other methylated forms of the 5ʹ-cap). This adenosine contains two methyl modifications: one at the 2ʹ position of the ribose ring and the other at the N 6 position of adenosine (Supplementary information S1 (table) ). Importantly, the residues that follow the methylated adenosine can be any base 50 . Due to the lack of a cytosine following and a guanosine immediately preceding the adenosine residue, these m 6 A residues differ from the GAC and AAC consensus motifs. Thus, methylation of these non-canonical m 6 A motifs might be mediated by other methyltransferases (FIG. 2a) .
There are numerous candidate methyltransferases that could mediate the methylation of these residues. METTL3 is part of a superfamily of at least three different types of mammalian methyltransferases of unclear function 73 . The adenosine methyltransferase activity that targets the U6 snRNA, which is different from METTL3 (REF. 28 ), could potentially target certain m 6 A residues in mRNA. Therefore, these or other enzymes could contribute to mRNA methylation. Interestingly, analysis of cellular extracts from mammalian cells produced two distinct adenosine methyltransferase activities, each of which could be partially purified into distinct fractions 74 . One fraction, similarly to METTL3, methylated diverse RNA templates; however, a separate activity selectively labelled RNA that contained a 5ʹ-cap 74 . As most studies of adenosine methylation used non-capped RNAs as substrates, the activity of the cap-dependent adenosine methyltransferase might have been missed and additional methyltransferases may also contribute to m 6 A formation in cells. A demethylases preferentially target mRNA or whether they target rRNA and snRNA has not yet been established; however, early evidence suggests a role for these enzymes in mRNA demethylation.
FTO.
The first enzyme that has been identified as an m 6 A demethylase is fat mass and obesity-associated protein (FTO) 5 . FTO has a controversial history, as numerous enzymatic activities have been ascribed to the enzyme. Bioinformatic analysis showed that FTO is a member of the superfamily of Fe(ii)-and 2-o xoglutarate-dependent oxygenases (Fe(ii)/2-OG-dependent oxygenases), which typically mediate oxygen transfer to specific target molecules 76, 77 . FTO has the highest homology to the AlkB subfamily of Fe(ii)/2-OG-dependent oxygenases, which comprises eight family members in humans and has known functions in nucleotide base demethylation reactions. These reactions occur by hydroxylation of methyl substituents on bases, forming a hydroxymethyl substituent 78, 79 . Hydroxymethyl substituents are highly unstable when connected to nitrogen atoms in a nucleotide base and spontaneously decompose to formaldehyde, which results in demethylation (FIG. 2b) . Thus, based on homology, FTO was thought to be potentially involved in similar hydroxylation-demethylation reactions.
Initial studies that demonstrated for the first time that FTO could mediate oxidative demethylation of nucleotide bases showed demethylation of 3-methylthymidine (3mT) in the context of single-stranded DNA 77 . A subsequent study demonstrated that FTO could also demethylat e 3-methyluracil (3mU) in single-stranded RNA 80 . Interestingly, 3mU is a minor constituent of rRNA 81 , which potentially links FTO to ribosome function.
Furthermore, m 6 A in RNA has been shown to be an additional substrate for FTO. One study showed that FTO demethylated m 6 A with a catalytic efficiency that was substantially higher than the activity of FTO towards 3mU A levels are generally unaffected in most mRNAs in Ftoknockout brain tissue 42 . However, for a small subset of mRNAs, m 6 A peaks are markedly higher in the Fto-knockout tissue than in the wild type 42 . Therefore, these data demonstrate that FTO demethylates mRNAs, although only a few m A-containing RNAs include certain ncRNAs, U6 snRNA, rRNA and pre-mRNAs. The proposed selectivity towards nuclear RNA was based on immunolabelling results showing that FTO is in nuclear speckles 5 . However, more recent results have demonstrated that FTO is also found in the cytoplasm in various cell types, including dopaminergic neurons, hypothalamic neurons and mouse embryonic fibroblasts 42, 82, 83 . Thus, FTO may also target cytosolic mRNAs, which would enable FTO to have roles in regulating cytosolic mRNA processing events.
The activity of FTO may involve the formation of oxidized m 6 A intermediates. Demethylation of m 6 A involves a hydroxylation reaction to form N 6 -hydroxymethyladenosine (hm 6 A) (Supplementary information S1 (table) ). This modification is highly labile and spontaneously decomposes to adenosine within a few hours. In vitro oxidative demethylation reactions using FTO also produces other oxidized species, such as N 6 -formyladenosine (f 6 A), in analogy to the diverse oxidized forms of cytosine that are generated by the FTO homologues ten-eleven translocation (TET) proteins 84 . It is not yet clear whether these labile oxidized intermediat es of m 6 A have specific functions. Studies of FTO target specificity and function will be facilitated by small-molecule inhibitors of FTO that will enable temporal regulation of the specific m 6 A residues. One such molecule is Rhein, a bioactive component of rhubarb that is a moderately selective FTO inhibitor 85 . The development of potent and selective inhibitors may be useful to influence physiological processes that are linked to FTO.
ALKBH5. Another recently described m 6
A demethylase is ALKBH5 (α-ketoglutarate-dependent dioxygenase alkB homologue 5), an FTO homologue of the AlkB family 6 . A systematic test of each of the nine mammalian AlkB homologues showed that ALKBH5 catalyses the demethylation of an m 6 A-containing RNA with nearly as high a rate as FTO, and it showed more specificity for demethylation of m 6 A than various other methylated nucleotides in single-stranded RNA 6 . ALKBH5 seems to affect mRNA export pathways. In ALKBH5-knockdown cells, increased levels of poly(A) mRNA were detected in the nucleus 6 , which suggests that ALKBH5 influences the expression of protein regulators of mRNA export. A more speculative hypothesis is that the mRNAs retained in the nucleus could be those that are hypermethylated in ALKBH5-knockdown cells. Although this idea is intriguing, it will require the demonstration that the retained and hypermethylated mRNAs in the nucleus are direct ALKBH5 targets.
Alkbh5-knockout mice grow to adulthood but with a marked increase in the levels of apoptotic cells in the testes 6 , which indicates a defect in spermatogenesis. The restriction of the knockout phenotype to testes is consistent with the distribution of the enzyme, which is primarily expressed in testes and at lower levels in the spleen and lung. It is intriguing that pheno types associated with m 6 A deficiency in lower organisms relate to gameto genesis and meiosis 57, 59, 64, 75 , which suggests an evolutionarily conserve d function for m 6 A in these processes.
It will be important to determine whether ALKBH5 demethylates mRNA, ncRNAs or both. ALKBH5 knockdown increased m 6 A levels in poly(A) mRNA by ~9%, whereas ~50-fold overexpression of ALKBH5 reduced m 6 A levels by ~29% (REF.
6) The subtle changes in the levels of m 6 A in cellular poly(A) mRNA suggest that this enzyme, similarly to FTO 42 , only demethylates certain m 6 A residues in mRNAs. Selected mRNAs were tested for their susceptibility to ALKBH5-mediated demethylation, which showed that in some cases the m 6 A level increased in ALKBH5-knockdown cells 6 . The identification of the specific ALKBH5 targets using MeRIP-Seq will be useful for characterizing the specificity of this enzyme.
What is the difference between these two demethylases, FTO and ALKBH5? Currently, the pathways that activate or inhibit these enzymes are unknown. However, ALKBH5 seems to be markedly enriched in the nucleus 6 , unlike FTO, which is readily detected in the cytosol 42, 82, 83 . Hence, ALKBH5 may target nuclear RNAs, whereas FTO may be capable of targeting mature mRNAs. The tissue distribution of these enzymes is another major difference. Whereas FTO is highly enriched in brain tissue 77 , ALKBH5 is predominantly expressed in testis and at substantially lower levels in other tissues 6 . Thus, ALKBH5 may confer demethylase activity in tissues that lack FTO and vice versa. MeRIP-Seq analysis of the ALKBH5-and FTO-specific targets will address whether these enzymes have redundant targets or whether they each target differen t types of mRNAs.
Mechanisms of m 6
A action Based on the localization of methyltransferase and demethylase enzymes, m 6 A may be introduced and removed in either the nucleus or the cytosol. Importantly, the role of m 6 A in nuclear mRNAs (that is, pre-mRNAs) may be different than its role in mature mRNAs in the cytosol. Currently, several functions have been ascribed to m 6 A that are beginning to tease apart these c ompartment-specific m 6 A roles.
Protein recruitment. m 6
A is likely to have a role in facilitating RNA-protein interactions. In principle, methylation of adenosine could either block or induce RNA-protein interactions (FIG. 3a) . To date, several m 6 A-binding proteins have been identified from mammalian cellular extracts using RNA pulldown approaches which are followed by mass spectrometry 4, 75, 86 . These include the mammalian proteins YTH domain-containing family 1 (YTHDF1), YTHDF2 and YTHDF3, each of which contains a YTH RNA-binding domain 87 . A YTH-domain-containing protein, methylated RNA-binding 1 (Mrb1), was also found to be an m A has been validated in vitro 86, 88 . The binding affinity ranged from 400 nM to ~1.2 μM 86, 88 . Although this binding is relatively weak compared with established sequencespecifi c RNA-protein inter actions 89 , it is possible that these protein s function by binding transiently to m [90] [91] [92] , will be essential for assessing the physiological targets of these RNA-binding proteins. These approaches involve crosslinking of mRNA with target proteins in live cells, which is followed by the recovery of the target proteins with bound RNA fragments. Analysis of the bound RNA enables the identification of the binding sites within the mRNA at near single-nucleotide resolution 90 . The major criteria for establishing that a putative m 6 A-binding protein is a bona fide interactor is that the binding sites of the protein need to precisely match m What kind of binding selectivity can be achieved with such a small modification as a methyl group? Based on our understanding of protein binding to methylated amino acids, it seems that considerable specificity can be achieved. For example, p53-binding protein 1 (53BP1), which binds methyl-Arg, exhibits a >20-fold increase in affinity between the non-methylated and methylated forms of a peptide ligand -52.9 μM and >1,000 μM, respectively 93 . Similarly, lethal (3) malignant brain tumour-like protein 1 (L3MBTL1), which binds methylLys in histone proteins, shows an ~80-fold increase in affinity between the non-methylated and methylated forms (6 μM and >500 μM, respectively) 94 . Thus, the methyl group on adenosine may introduce a >20-fold binding selectivity.
Conformational changes. m
6 A can also affect RNA by altering RNA structure or folding. The two hydrogen bonds that constitute the A•U base pair still form if the adenosine is methylated, but they are slightly destabilized 95 (FIG. 3b) . Although the overall effect of methylation on the stability of an RNA duplex is subtle, it could influence certain types of interactions in which duplex stability is particularly important, such as miRNA-mRNA interactions 96 . Therefore, subtle alterations in binding (FIG. 3b) . This interaction will not form if the N 6 position is methylated, as both hydrogens on this nitrogen are hydrogen bond donors in the base triple. Hence, the formation of A-A•U base triples is blocked by methylation. A-U•A base triples have been seen in several mammalian ncRNAs, including nuclearenriched abundant transcript 1 (NEAT1; also known as MENβ/ε) and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) 79 . Interestingly, based on MeRIP-Seq analysis 3 , MALAT1 also contains m 6 A. Thus, methylation could act as a trigger to disrupt RNA structures that depend on hydrogen bonding of both N 6 hydrogen s on adenosine. A was as a regulator of splicing (FIG. 3c) . This was initially based on studies that characterized the m 6 A content of the pre-mRNA in the nucleus and compared it to the m 6 A content in mature cytoplasmic mRNA. In these studies, pre-mRNA was found to be methylated at ~4 m 6 A residues per mRNA, whereas the mature mRNA was methylated at ~2 m 6 A residues per mRNA 32 . These studies documented that methylation occurs in the nucleus and suggested that the removal of introns resulted in the loss of total m 6 A content per mRNA. More recent studies support this idea. PAR-CLIP analysis shows that most METTL3-binding sites in transcripts occur in introns 61 . Thus, intronic sequences may be a major target of nuclear methylation. The localization of METTL3 and METTL14 to nuclear speckles also supports the idea that m 6 A is linked to splicing, and these sites may enable intronic methylation.
MeRIP-Seq does not fully support the concept that methylation is highly targeted to introns; studies showed that m 6 A was preferentially found in exons, and only ~5-7% of m 6 A peaks were present in introns 3,4 . However, MeRIP-Seq studies to date have been carried out on steady state cellular RNA, which contains a low concentration of the highly labile pre-mRNA and introns. Hence, m 6 A may be introduced into introns at a relatively high level, which is then followed by rapid intron excision and degradation. Although the prevalence and distribution of m 6 A within intronic sequences needs to be more thoroughly examined by carrying out MeRIP-Seq on pre-mRNA, one possibility is that m 6 A is targeted to specific intronic regions to influence splicin g efficiency. A-containing dihydrofolate reductase (DHFR) mRNA was increased by about 50% compared with unmethylated mRNA 98 . However, more recent studies using both in vitro translation and transfection of reporter mRNAs into cells have shown that adenosine methylation leads to reduced translation compared with unmethylated transcripts 99 (FIG. 3d) . Thus, the effects of m 6 A on protein production do not seem to be uniform among different mRNAs. One possibility is that this effect is determined in part by other cis-acting factors within the transcript, or perhaps that the location of m 6 A within an mRNA influences its ability to interact with specific trans-acting factors that mediate its effects on translation. A is needed for normal mRNA expression level s. A possible explanation for these data is that m 6 A is needed for proper splicing of mRNA, which when disrupted results in impaired splicing and subsequen t mRNA degradation.
Studies using Fto-knockout mice provide an opportunity to determine how altered m 6 A levels influence mRNA abundance and protein production. In these mice, five mRNAs that were tested had increased m 6 A peaks (that is, hypermethylated mRNAs) and also exhibited slightly increased mRNA levels, but there was no consistent effect on the level of the encoded proteins: in some cases, protein levels were decreased, whereas for other transcripts the protein levels were slightly increased or were unchanged 42 . Furthermore, other reports suggest that m 6 A promotes mRNA degradation 63, 86 (FIG. 3e) . One study focused on YTHDF2, a mammalian protein that was first identified to bind to m 6 A using pulldown approaches 4 . YTHDF2 was shown to promote mRNA degradation of thousands of cellular transcripts 86 . Consistent with this idea, YTHDF2 is found in a subset of cellular processing bodie s (P-bodies). Additionally, PAR-CLIP studies probing the binding sites of overexpressed epitope-tagged YTHDF2 identified target mRNAs that are also known to contain m 6 A. In some transcripts, the PAR-CLIP site overlaps with the m 6 A peak 86 . Further analysis will be required to define the specific identity and number of m 6 A-containing mRNAs that are subjected to YTHDF2 regulation in cells.
Another study used Mettl3 and Mettl14 knockdown to identify mRNAs that were methylated by these methyltransferases and monitored the stability of these mRNAs in mouse embryonic stem cells 63 . In knockdown cells, many METTL3-and METTL14-target mRNAs showed a modest increase in stability, which suggests that m 6 A functioned to induce mRNA instability (FIG. 3e) A reduces HuR bindin g, thereby facilitating mRNA degradation.
In both studies, the effect of m 6 A on mRNA stability was measured by monitoring total mRNA levels. As every mRNA exists as a pool of both methylated and nonmethylate d forms, it will be important to directly follow the fate of only the mRNA molecules that contain m A in 3ʹ UTRs and the presence of miRNA-binding sites suggests an interplay between mRNA methylation and mi RNAs. It is possible that the presence of an miRNA-binding site induces pathways that lead to mRNA methylation. Indeed, in the brain, mRNAs that contain brain-enriched miRNAbinding sites were more likely to have an m 6 A residue than mRNAs that contain sites for mi RNAs that are not abundant in the brain 3 . It will be important to determine whether adenosine methylation contributes to the actions of miRNA-induced mRNA silencing.
Future directions
The results of transcriptome-wide m A and how mRNA methylation is regulated remain poorly understood, despite many important recent advances. Resolving these issues will require efforts on several different fronts.
An important next step will be to develop approaches for higher resolution mapping of m 6 A in the mammalian transcriptome. This will enable researchers to selectively mutate specific adenosine residues and determine how methylation regulates the fate of an mRNA. Furthermore, precise m 6 A mapping is needed to define the specific m 6 A residues that are bound to putative m 6 A-binding proteins. MeRIP-Seq involves immunoprecipitation of ~100 nucleotide-long fragments, which therefore results in peaks that are approximately 200 nucleotides in resolution. The use of smaller RNA fragments has recently been described, which provides greater resolution 75 . This approach was used to map m 6 A sites in yeast, and its successful application to more complex transcriptomes has not yet been established. Other approaches to achieve higher resolution can be envisaged, for example by crosslinking cellular RNA to m 6 A antibodies and by analysing the crosslinking site using methods that have been highly optimized for HITS-CLIP and related techniques [90] [91] [92] . Last, the inclusion of control RNAs with known m 6 A stoichiometry could be used as standards to obtain absolute measures of m 6 A stoichiometry. These strategies will be essential to more precisely define the specific modified m 6 A residues in the transcriptome and the degree of methylation at specific adenosines within a transcript.
A major goal will be to determine how m 6 A affects the fate of mRNA. In addition, there is a need to understand whether all m 6 As have the same function or whether their distribution within a transcript dictates their role in mRNA processing. A crucial step in this process will be the identification of m 6 A-binding proteins and the demonstration that endogenous proteins bind mRNAs at m A is its potential to be reversed by FTO or ALKBH5. As mutations in FTO are linked to various diseases and altered neuronal function 42, 101, 102 , the identification of physiological signalling pathways that trigger m 6 A demethylation are particularly important. However, evidence for dynamic reversibility of m 6 A in mRNA has not been established. The recent identification of mRNAs that are targeted by FTO 42 is a first step in deciphering these demethylation pathways.
Similarly, it is not clear why certain mRNAs are targeted for methylation. This is an outstanding puzzle, as all mRNAs contain the GAC consensus motif, but only a fraction of cellular mRNAs seem to be targeted for methylation. Thus, the factors that determine whether an mRNA will be methylated are unknown. Identifying cis-acting elements in mRNAs that render an mRNA susceptible to methylation will be important for ultimately deciphering the methylation specificity in cells.
As mentioned above, m 6 A stoichiometry varies greatly among different mRNAs. The factor that selects an mRNA as a target for high stoichiometry methylation remains unclear, but it is likely to be the trigger that diverts an mRNA into an m 6 A-regulated processing
